Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

Stopped early · Phase 3

Conditions studied: Leukemia, Lymphoma

In brief

The goal of this clinical research study is to learn if intense management and control of blood sugar levels during treatment for acute lymphocytic leukemia, Burkitts lymphoma, or lymphoblastic lymphoma will result in decreased risk of relapse, fewer complications, and/or longer survival.

Key facts

Study ID

NCT00500240

Run by

M.D. Anderson Cancer Center

People needed

52

Starts

2004-04-01

Expected to finish

2012-04-01

Last updated by the study team

2015-06-03

Who can join

Age: 15 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >/= 15 years.
• Previously untreated ALL, Burkitt's lymphoma, or lymphoblastic leukemia receiving induction chemotherapy with hyper-CVAD or variants of the hyper-CVAD regimen.
• Random serum glucose >/= 180 mg/dL detected during the first 2 cycles of chemotherapy and confirmed with a second measurement.

You may not qualify if…

• History of Type I diabetes mellitus.
• Pregnancy or breast feeding.
• Allergy to insulin or insulin products.
• On-going treatment of steroid-induced hyperglycemia by an endocrinologist and/or general internist.

Where it is running

• UT MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.